Furlanetto, Jenny
Jackisch, Christian
Untch, Michael
Schneeweiss, Andreas
Schmatloch, Sabine
Aktas, Bahriye
Denkert, Carsten
Wiebringhaus, Hermann
Kümmel, Sherko
Warm, Mathias
Paepke, Stefan
Just, Marianne
Hanusch, Claus
Hackmann, John
Blohmer, Jens Uwe
Clemens, Michael
Costa, Serban Dan
Gerber, Bernd
Nekljudova, Valentina
Loibl, Sibylle
von Minckwitz, Gunter
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69)
https://doi.org/10.1007/s10549-017-4200-1
Funding for this research was provided by:
GBG Forscungs GmbH
Article History
Received: 15 November 2016
Accepted: 13 March 2017
First Online: 17 March 2017
Compliance with ethical standards
:
: Denkert C: Shareholder and cofounder of Sividon Diasgnostics Cologne, Hanusch C: Honoraria by Celgene and Roche, Jakisch C: Honoraria by Celgene, Loibl S: Institution received research grants by Celgene and Roche, von Minckwitz G: Institution received research grants by Celgene and Roche. All other authors have declared no conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the GeparSepto study.